FinEdge Labs
O

OGN

OGN
34 segments tracked|5 years of data|Annual (10-K)
Total Revenue
$3.8B40.7%
FY2025
Operating Segments
34
Active segments
Blended Margin
0.0%
Operating margin
Highest Margin
0.0%
Nexplanon Implanon NXT
Segment Shift

Nexplanon Implanon NXT has grown from 13.4% to 25.4% of total revenue since FY2021, with 0.0% operating margins.

Segment Revenue Over Time

Revenue Mix

Segment Breakdown — FY2025

SegmentRevenueOp. IncomeMargin% of TotalYoY
Nexplanon Implanon NXT$963M$00.0%25.4%+0.0%
Atozet$473M$00.0%12.5%+0.0%
Singulair$359M$00.0%9.5%+0.0%
Other Sundry Established Brands$328M$00.0%8.6%+0.0%
Zetia$317M$00.0%8.3%+0.0%
Other Non Opioid Pain Bone And Dermatology$295M$00.0%7.8%+0.0%
Nasonex$276M$00.0%7.3%+0.0%
Renflexis$274M$00.0%7.2%+0.0%
Arcoxia$270M$00.0%7.1%+0.0%
Cozaar Hyzaar$243M$00.0%6.4%+0.0%

Want more? Unlock the full analysis.

Sign up free to access quarterly data, financial statements, trend analysis, geographic segments, Excel exports, and cross-company comparisons.

Get Started Free